Hengrui Medicine: Subsidiary SHR-A2102 and Adelbeii monoclonal antibody injection receive clinical trial approval.

"Hengrui Pharmaceuticals announced that its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd., Shanghai Hengrui Pharmaceuticals Co., Ltd., and Shanghai Shengdi Pharmaceuticals Co., Ltd. have received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for injection SHR-A2102 and Atezolizumab injection. Clinical trials will be conducted soon. Injection SHR-A2102 is a targeted antibody drug conjugate against Nectin-4 developed independently by the company with intellectual property rights, and Atezolizumab injection is a humanized anti-PD-L1 monoclonal antibody independently developed by the company."